Imaging end points for monitoring neuroprotection in Parkinson's disease
Identifieur interne : 002868 ( Main/Corpus ); précédent : 002867; suivant : 002869Imaging end points for monitoring neuroprotection in Parkinson's disease
Auteurs : David J. BrooksSource :
- Annals of Neurology [ 0364-5134 ] ; 2003.
Abstract
In this review, the potential role of positron emission tomography and single‐photon emission computed tomography as biological markers for following the progression of Parkinson's disease (PD) is discussed, and their value for assessing the efficacy of putative neuroprotective agents in PD is considered. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD. Ann Neurol 2003;53: (suppl 3)S110–S119
Url:
DOI: 10.1002/ana.10480
Links to Exploration step
ISTEX:BCFC852058D983C73E6E3B195D2EFDA70E73F81ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Imaging end points for monitoring neuroprotection in Parkinson's disease</title><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation><mods:affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BCFC852058D983C73E6E3B195D2EFDA70E73F81E</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/ana.10480</idno><idno type="url">https://api.istex.fr/document/BCFC852058D983C73E6E3B195D2EFDA70E73F81E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002868</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Imaging end points for monitoring neuroprotection in Parkinson's disease</title><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation><mods:affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2003">2003</date><biblScope unit="volume">53</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">3</biblScope><biblScope unit="page" from="S110">S110</biblScope><biblScope unit="page" to="S119">S119</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">BCFC852058D983C73E6E3B195D2EFDA70E73F81E</idno><idno type="DOI">10.1002/ana.10480</idno><idno type="ArticleID">ANA10480</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In this review, the potential role of positron emission tomography and single‐photon emission computed tomography as biological markers for following the progression of Parkinson's disease (PD) is discussed, and their value for assessing the efficacy of putative neuroprotective agents in PD is considered. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD. Ann Neurol 2003;53: (suppl 3)S110–S119</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>David J. Brooks MD, DSc, FRCP, FMedSci</name><affiliations><json:string>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</json:string></affiliations></json:item></author><articleId><json:string>ANA10480</json:string></articleId><language><json:string>eng</json:string></language><abstract>In this review, the potential role of positron emission tomography and single‐photon emission computed tomography as biological markers for following the progression of Parkinson's disease (PD) is discussed, and their value for assessing the efficacy of putative neuroprotective agents in PD is considered. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD. Ann Neurol 2003;53: (suppl 3)S110–S119</abstract><qualityIndicators><score>5.84</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 801 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>499</abstractCharCount><pdfWordCount>6929</pdfWordCount><pdfCharCount>43252</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>70</abstractWordCount></qualityIndicators><title>Imaging end points for monitoring neuroprotection in Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>53</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>10</total><last>S119</last><first>S110</first></pages><issn><json:string>0364-5134</json:string></issn><issue>S3</issue><subject><json:item><value>Research Articles</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>2003</publicationDate><copyrightDate>2003</copyrightDate><doi><json:string>10.1002/ana.10480</json:string></doi><id>BCFC852058D983C73E6E3B195D2EFDA70E73F81E</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/BCFC852058D983C73E6E3B195D2EFDA70E73F81E/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/BCFC852058D983C73E6E3B195D2EFDA70E73F81E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/BCFC852058D983C73E6E3B195D2EFDA70E73F81E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Imaging end points for monitoring neuroprotection in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><availability><p>WILEY</p></availability><date>2003</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Imaging end points for monitoring neuroprotection in Parkinson's disease</title><author><persName><forename type="first">David J.</forename><surname>Brooks</surname></persName><roleName type="degree">MD, DSc, FRCP, FMedSci</roleName><note type="correspondence"><p>Correspondence: Hartnett Professor of Neurology. MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom</p></note><affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2003"></date><biblScope unit="volume">53</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">3</biblScope><biblScope unit="page" from="S110">S110</biblScope><biblScope unit="page" to="S119">S119</biblScope></imprint></monogr><idno type="istex">BCFC852058D983C73E6E3B195D2EFDA70E73F81E</idno><idno type="DOI">10.1002/ana.10480</idno><idno type="ArticleID">ANA10480</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2003</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>In this review, the potential role of positron emission tomography and single‐photon emission computed tomography as biological markers for following the progression of Parkinson's disease (PD) is discussed, and their value for assessing the efficacy of putative neuroprotective agents in PD is considered. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD. Ann Neurol 2003;53: (suppl 3)S110–S119</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Articles</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2003">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/BCFC852058D983C73E6E3B195D2EFDA70E73F81E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="subtitle">Official Journal of the American Neurological Association and the Child Neurology Society</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="45"><doi origin="wiley" registered="yes">10.1002/ana.v53:3+</doi><titleGroup><title type="supplementTitle">Neurogeneration and Prospects for Neuroprotection and Rescue in Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="53">53</numbering><numbering type="journalIssue">S3</numbering><numbering type="supplement" number="3">3</numbering></numberingGroup><coverDate startDate="2003">2003</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="11" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.10480</doi><idGroup><id type="unit" value="ANA10480"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="articleCategory">Research Articles</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="publisher">Copyright © 2003 Wiley‐Liss, Inc.</copyright><eventGroup><event type="firstOnline" date="2003-03-24"></event><event type="publishedOnlineFinalForm" date="2003-03-24"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.1 mode:FullText source:FullText result:FullText" date="2010-02-23"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">S110</numbering><numbering type="pageLast">S119</numbering></numberingGroup><correspondenceTo>Hartnett Professor of Neurology. MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA10480.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="67"></count><count type="wordTotal" number="7780"></count></countGroup><titleGroup><title type="main" xml:lang="en">Imaging end points for monitoring neuroprotection in Parkinson's disease</title><title type="short" xml:lang="en">Monitoring Neuroprotection in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>David J.</givenNames><familyName>Brooks</familyName><degrees>MD, DSc, FRCP, FMedSci</degrees></personName><contactDetails><email>david.brooks@csc.mrc.ac.uk</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In this review, the potential role of positron emission tomography and single‐photon emission computed tomography as biological markers for following the progression of Parkinson's disease (PD) is discussed, and their value for assessing the efficacy of putative neuroprotective agents in PD is considered. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD. Ann Neurol 2003;53: (suppl 3)S110–S119</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Imaging end points for monitoring neuroprotection in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Monitoring Neuroprotection in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Imaging end points for monitoring neuroprotection in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">David J.</namePart><namePart type="family">Brooks</namePart><namePart type="termsOfAddress">MD, DSc, FRCP, FMedSci</namePart><affiliation>MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</affiliation><description>Correspondence: Hartnett Professor of Neurology. MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2003</dateIssued><copyrightDate encoding="w3cdtf">2003</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="references">67</extent><extent unit="words">7780</extent></physicalDescription><abstract lang="en">In this review, the potential role of positron emission tomography and single‐photon emission computed tomography as biological markers for following the progression of Parkinson's disease (PD) is discussed, and their value for assessing the efficacy of putative neuroprotective agents in PD is considered. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD. Ann Neurol 2003;53: (suppl 3)S110–S119</abstract><relatedItem type="host"><titleInfo><title>Annals of Neurology</title><subTitle>Official Journal of the American Neurological Association and the Child Neurology Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Articles</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><detail type="issue"><caption>no.</caption><number>S3</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>3</number></detail><extent unit="pages"><start>S110</start><end>S119</end><total>10</total></extent></part></relatedItem><identifier type="istex">BCFC852058D983C73E6E3B195D2EFDA70E73F81E</identifier><identifier type="DOI">10.1002/ana.10480</identifier><identifier type="ArticleID">ANA10480</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2003 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002868 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002868 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:BCFC852058D983C73E6E3B195D2EFDA70E73F81E
|texte= Imaging end points for monitoring neuroprotection in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |